After more than two years in the making, two outside gene therapy consortia are underway in the US to help broaden the consensus starting point on discussions with CBER on characterization assays and the appropriate use of surrogate endpoints.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?